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Abstract
Background: Good adherence to antiretroviral therapy is necessary to achieve the best virological response, lower
the risk that drug resistance will develop, and reduce morbidity and mortality. Little is known about the rate and
predictors of adherence in Ethiopia. Therefore this study determines the magnitude and predictors of adherence to
antiretroviral therapy among people living with HIV/AIDS in Southwest Ethiopia.
Methods: A cross sectional study was carried out from January 1, 2009 to March 3, 2009 among 319 adult PLWHA
(≥ 18 years) attending ART clinic at Jimma university Specialized Hospital (JUSH). Multiple Logistic regression
models were constructed with adherence and independent variables to identify the predictors.
Results: About 303(95%) of the study subjects were adherent based on self report of missed doses (dose
adherence) in a one-week recall before the actual interview. The rate of self reported adherence in the study based
on the combined indicator of the dose, time and food adherence measurement was 72.4%. Patients who got
family support were 2 times [2.12(1.25-3.59)] more likely to adhere than those who didn’t get family support as an
independent predictor of overall adherence (dose, time and food). The reasons given for missing drugs were 9
(27.3%) running out of medication/drug, 7(21.2%) being away from home and 7(21.2%) being busy with other
things.
Conclusion: The adherence rate found in this study is similar to other resource limited setting and higher than the
developed country. This study highlights emphasis should be given for income generating activities and social
supports that helps to remember the patients for medication taking and management of opportunistic infections
during the course of treatment.
Background
The number of people living with HIV worldwide con-
tinued to grow in 2008, reaching an estimated 33.4 mil-
lion [31.1 million-35.8 million]. Sub-Saharan Africa
remains the region most heavily affected by HIV. In
2008, sub-Saharan Africa accounted for 67% of HIV
infections worldwide, 68% of new HIV infections among
adults. The region also accounted for 72% of the world’s
AIDS-related deaths in 2008 [1]. World Health Organi-
zation (WHO) recommendations on the use of antire-
troviral therapy in resource-limited settings recognize
the critical role of adherence in order to achieve clinical
and programmatic success [2]. Good adherence to anti-
retroviral therapy is necessary to achieve the best virolo-
gical response, lower the risk that drug resistance will
develop, and reduce morbidity and mortality [3]. How-
ever, adherence barriers vary in different settings and
lessons from more developed countries [4]. These bene-
fits critically depend on patients achieving and maintain-
ing high levels of medication adherence [5]. Very high
levels of adherence (> 95%) are required for ART to be
effective for long term and to prevent the emergence of
resistant viral strains [6]. There has been a concern
about the capability of patients in resource-limited
settings to adhere to ART, especially in the African
context [7].
Both clinical experience and emerging data suggest
that many patients with chronic HIV disease do not
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any medium, provided the original work is properly cited.fully adhere to their Highly Active Antiretroviral Ther-
apy (HAART) regimens [8-11]. Incomplete adherence to
antiretroviral agents can have serious consequences,
including loss of plasma HIV suppression and turn lead
to disease progression, inability to suppress HIV even
with very intensive regimens, and development of drug
resistant HIV strains. This can in transmission of resis-
tant HIV to others [12-17].
However, introducing ART to sub-Saharan Africa was
a topic of hot debate just a few years ago. Concerns
about adherence and subsequent development of drug
resistance, poor infrastructure, logistic and human capa-
city, and cost-effectiveness were the major issues [18].
In Ethiopia, the antiretroviral treatment program started
with a fee-based ART program in 2003 then decentra-
lized and free ART program in the Country was lunched
since 2005[19]. Consequently, non-adherence to the
proposed antiretroviral regimen is considered to be one
of the greatest dangers to the response to treatment on
an individual level and the dissemination of resistant
viruses on the community level [20]. Little is known
about the rate and predictors of adherence in Ethiopia.
Therefore, this study determines the magnitude and pre-
dictors of adherence to antiretroviral therapy among
people living with HIV/AIDS in Southwest Ethiopia.
Methods
Study setting
The study was conducted in Jimma University Specia-
lized Hospital (JUSH). It is the only specialized referral
Hospital in Southwest Ethiopia. Currently, it is giving
service to more than 15,000,000 people living in South-
west Ethiopia. In 2002, the ART clinic of the hospital
started its activity. After the government launched free
ART in 2005, the hospital started to provide free service
to People Living with HIV/AIDS (PLWHA). The study
was conducted from January 1, 2009 to March 3, 2009
for a period of 2 month. The study design was a facility-
based cross-sectional study. Institutional Ethical Review
Committee of Jimma University approved the study and
materials. All study subjects gave verbal informed
consent.
Participants
The source populations were all PLWHA on Highly
Active Antiretroviral Treatment registered and following
their treatment in Jimma University Specialized Hospital
(JUSH). The study population for this study were adults
who can fulfill the inclusion criteria- all PLWHA on
HAART whose age is > 18 years regardless of their
treatment category during the study period and available
during data collection period. The exclusion criteria
were: those patients on HAART whose age is < 18
years, adult (> 18 years) PLWHA who have been on
treatment for less than 3 month period; potential parti-
cipants at screening if they reported diabetes mellitus,
current pregnancy. The sample size was calculated using
Epi-info software version 6.04 StatCalc. Sample size was
calculated using the 50% proportion (50% of respondent
considered as adherence). A precision of 5% and with
95% confidence level was taken. A sample size was 290
which after adding 10% for non-response gave an overall
sample size of 319. The study participants were selected
randomly using a computer generated simple random
table based on patient ART unique identification
number.
Measurement
The dependent variable was adherence to HAART
among PLWHA. The independent variables were socio-
economic status, socio-demographic factor, clinical char-
acteristics, associated diseases and symptoms like diar-
rheal disease, anorexia, behavioral factors- alcohol
intake, smoking habit, substance addiction. A structured
pre-tested questionnaire which is developed from differ-
ent literatures was used for data collection purpose. The
questionnaire contains information on socio-demo-
graphic (age, sex, education, occupation, marital status),
socio-economic variables(family income), psychosocial
(social support, depression, active substance and alcohol
use, disclosure of HIV serostatus, use of memory aids),
disease characteristics (WHO clinical staging, duration
of HIV infection), regimen related variables (dosing
schedules and frequency, pill burden and complexity,
dietary related demands, side effect, history of hospitali-
zation), adherence to treatment information, symptoms
associated with treatment. To identify clinical markers
medical record was reviewed.
Data analysis and processing
Data were edited, cleaned, coded and entered in to a
computer and analyzed using SPSS- for windows version
16.0. Descriptive statistics was done to assess basic client
characteristics. Bivariate analysis was done to determine
presence of statistically significant association between
explanatory variables and the outcome variable. All
explanatory variables that were associated with the out-
come variable in bivariate analyses were included in the
final model. Multiple Logistic regression model was con-
structed with adherence and the independent variables
to identify the predictors. The model was evaluated
using forward stepwise selection method. Chi-square
test and their p-values at the level of significance of 5%
were used to define statistical associations between vari-
ables. Odds Ratios (OR) and their 95% CI were used to
look into the strength of association between the depen-
dent and independent variables. A person was said to be
food adherent if he/she always followed dietary
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he/she was labeled as non-adherent (Self-reported food
adherence). Self-reported time adherence- where a per-
son is said to be time adherent when claiming to always
follow scheduling instructions otherwise non-adherent.
Patients’ self-report of whether any antiretroviral medi-
cation had been skipped on the day of interview, the
previous day, the previous three days and the previous
seven days before the interview was used to assess
adherence to HAART. A person is said to be dose
adherent when he/she took ≥ 95% of the prescribed
doses correctly otherwise non-adherent (Self-reported
dose adherence). Hence, for comparison purposes a
combined indicator of adherence was made using the
three adherence measures taking into account all ques-
tions pertaining adherence. So in this study Adherent is
defined as when a PLWHA takes more than 95% (not
missing a single doses of ART) of prescribed drug (dose
adherence), follows time restriction (time adherence)
and dietary instruction from health care provider (food
adherence) for one week prior to the study otherwise
Non-Adherent. This type of measurement of adherence
has been used in similar setting and adherence in the
previous seven days was used for comparison [21]. To
assure quality of the data, the questionnaire was pre
tested on PLWHA (5% of the sample size i.e. 21 indivi-
duals) and modifications were incorporated to the ques-
tionnaire and not included in the actual study. The
interview was conducted in private room to create an
atmosphere of empathy and confidence within a secure
environment. An intensive 2 days training was given for
all supervisors and data collectors before the process of
data collection. The overall activity was controlled by
the principal investigator of the study and proper
designing of the data collection materials and continues
supervision during data collection was performed. All
completed questionnaire was examined for completeness
and consistency during data management, storage and
analysis.
Results
Socio demographic and economic characteristics
A total of 319 adult PLWHA participated in the study
giving a response rate of 100%. Out of 319 PLWHA the
largest number of participants, 148(46.4%) were in the
age group 25-34 years and the mean (SD) age of the
respondents was 35.08(7.73) ranging from 19 to 64 years
and female constitutes 175(54.9%). The majority of the
respondents 271(85.0%) were from Jimma City, 142
(44.5%) participants were Oromo by ethnicity, 162
(50.8%) Orthodox by religion, 155(48.6%) were married.
The majority of them had 162(50.8%) attended elemen-
tary school. One hundred twenty nine (40.4%) were
employed in private or governmental organizations and
174(54.5%) live with their parents. The median monthly
income of the participants and their family were 300.00
and 350.00 Ethiopian Birr respectively, while weekly
median expenditure for different purposes and for food
preparation and purchasing were 100.00 and 50.00
Ethiopian Birr, respectively. The socio-demographic and
economic characteristics of participants are presented in
Table 1.
Clinical characteristics of the participants
Based on the review of patients’ records, most of the
participants 229(71.8%) were currently taking HAART
with a regimen of Stavudine (d4T), Lamivudine (3TC)
and Nivirapine (NVP) combination. Most of the partici-
pants 173(54.2%) started treatment in stage III of WHO
disease classification and 217(71.1%) had a CD4 count
of ≤ 200 cells/mm3 at the start of treatment and 155
(60.3%) of the participants had recent CD4 count 201-
499 cells/mm
3; the range being 3 to 500 cells/mm3 and
42 to 1,230 cells/mm
3 with median of 144 cells/mm3
and 340 cells/mm3 at the beginning of treatment and
recently at the time of data collection, respectively.
Those who did not have CD4 count at the initiation of
treatment had a median total lymphocyte count (TLC)
of 1,000 cell/mm
3 with ranges from 700 cell/mm
3 to
2,103 cell/mm
3. The majority of respondents 191(59.9%)
received HAART for a duration of greater than 24
months with a mean duration of 26 months (Table 2).
Disclosure status, psychosocial support and behavioral
factors of the participants
Majority of the respondents 290(90.9%) disclosed their
HIV results to at least one person. One Hundred fifty
(51.7%) of the respondents disclosed to their friends and
147(50.7%) to their wife or husbands, respectively. More
females disclosed than males (56.6% Vs 43.4%). Majority
of the respondents 265 (83.1) get family support (Table
3). The majority of the respondents did not take any
substance; only 23(7.2%) of the participants take at least
one type of substance (smoking, taking alcohol, chewing
khat or other drugs). Out of these 10(3.1%) of them
drunk alcohol, 17(5.3%) chewed khat and majority of
them take those substance occasionally.
Rates of adherence and reasons for non adherence
The three adherence measurements were assessed in the
study to get a combined adherence indicator (Table 4).
These include self reported missed doses, self reported
schedule/time adherence and self reported food adher-
ence. Accordingly, 303(95%) of the study subjects were
adherent based on self report of missed doses (dose
adherence) in a one-week recall. Two hundred fifty five
(79.9%) of the study subjects always follow the schedule/
time restrictions (time adherence) agreed upon with
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(Food Adherence). Hence, the rate of self reported
a d h e r e n c ei nt h es t u d ya r e ab a s e do nt h ec o m b i n e d
indicator of the dose, time and food adherence measure-
ment was 231(72.4%). The reasons given for missing
drugs were running out of medication/drug 9(27.3%),
being away from home 7(21.2%) and being busy with
other things 7(21.2%) and the rest reasons included sim-
ply forgetting, having no food to take with the medica-
tion, fear of side effect and feeling sick or ill at that time
(Figure 1).
Predictors of adherence to HAART
The association of overall adherence (dose, time and
food) with different variables were examined using binary
logistic regression and there is a significant association
(p < 0.05) identified with WHO stage, average family
income, getting family support and sex and adherence of
ART. Patients who got family support were 2 times [2.12
(1.25-3.59)] more likely to adhere than those who didn’t
get family support as an independent predictor of overall
adherence (dose, time and food) (Table 5).
Discussion
Antiretroviral therapy (ART) adherence levels of ≥ 95%
optimize outcomes and minimize HIV drug resistance
and to optimize measures of patient outcomes [22]. Pre-
vious studies in Ethiopia were using only self reported
dose adherence as a measurement [23-25]. In our study
we also used the time restriction (time adherence) and
instructions related to food (food adherence) in addition
to self reported dose adherence measurement. Our data
suggest that adherence rates among patients in south-
west Ethiopia were higher than adherence rates in most
developed countries. In this study measuring adherence
Table 1 Socio-demographic and economic characteristics
of the study participants, Jimma University Specialized
Hospital (JUSH), Southwest Ethiopia, 2009
Characteristics Frequency(Percentage)
Sex
Male 144(45.1)
Female 175(54.9)
Age
18-24 15(4.7)
25-34 148(46.4)
35-44 115(36.1)
≥ 45 41(12.9)
Permanent address
Jimma 271(85.0)
Out of Jimma 48(15.0)
Ethnicity (N = 319)
Oromo 142(44.5)
Amhra 84(26.3)
Dawro 40(12.5)
Kefa 24(7.5)
Gurage 15(4.7)
Others* 14(4.4)
Marital Status
Married 155(48.6)
Single 67(21.0)
Windowed 43(13.5)
Divorced/Separated 54(16.9)
Educational status
Illiterate 32(10.0)
Elementary 162(50.8)
Secondary 90(28.2)
12+ 35(11.0)
Occupation
Employed 129(40.4)
Merchant 31(9.7)
House Wife 42(13.2)
Daily laborer 84(26.3)
Have no job 20(6.3)
Others *** 13(4.1)
Living With
Alone 77(24.1)
Family 54(16.9)
Parents 174(54.5)
Other 14(4.4)
Average Monthly income (N = 267)
≤ 500 200(74.9)
501-999 26(9.7)
≥ 1000 41(15.4)
Table 1 Socio-demographic and economic characteristics
of the study participants, Jimma University Specialized
Hospital (JUSH), Southwest Ethiopia, 2009 (Continued)
Religion
Orthodox 162(50.8)
Muslim 78(24.5)
Protestant 68 (21.3)
Others** 11(3.4)
Average Family Income (N = 306)#
≤ 500 216(70.6)
501-999 33(10.8)
≥ 1000 57(18.6)
*Tigre, Yem, Wolayita, Kenbata, Sidama, Bench,
**Catholic, Jova whiteness,
*** Farmer, Bar,
# Exchange rate 1 USD = 13 Ethiopian Birr (ETB)
Tiyou et al. AIDS Research and Therapy 2010, 7:39
http://www.aidsrestherapy.com/content/7/1/39
Page 4 of 10Table 2 Clinical markers of the study participants comparing male and female using a Chi Square test, JUSH, South
West Ethiopia, 2009
Characteristics Male
No. (%)
Female
No. (%)
Total
No. (%)
P - value
WHO disease stage when HAART started (N = 319) 0.075
I 7(4.9) 5(2.9) 12(3.8)
II 35(24.3) 43(24.6) 78(24.5)
III 85(59.0) 88(50.3) 173(54.2)
IV 17(11.8) 39(22.3) 56(17.6)
CD4 count when the treatment was started (N = 305) 0.298
≥ 500 1(0.7) 0(0.0) 1(0.3)
201-499 43(30.5) 44(26.8) 87(28.5)
≤ 200 97(68.8) 120(73.2) 217(71.1)
Recent CD4 count (N = 257) 0.111
≥ 500 22(18.5) 38(27.5) 60(23.3)
201-499 73(61.3) 82(59.4) 155(60.3)
≤ 200 24(20.2) 18(13.1) 42(16.3)
Duration of treatment in months (N = 319) 0.877
3.0-12.0 25(17.4) 28(16.0) 53(16.6)
12.1-24.0 35(24.3) 40(22.9) 75(23.5)
≥ 24.1 84(58.3) 107(61.1) 191(59.9)
Treatment regimen(N = 319) 0.549
d4t (30)- 3TC-NVP 88(61.1) 115(65.7) 203(63.6)
d4t (40)- 3TC-NVP 12(8.3) 14(8.0) 26(8.2)
d4t (30)- 3TC-EFV 21(14.6) 17(9.7) 38(11.9)
d4t (40)- 3TC-EFV 5(3.5) 3(1.7) 8(2.5)
AZT-3TC-NVP 16(11.1) 25(14.3) 41(12.9)
AZT-3TC-EFV 2(1.4) 1(0.6) 3(0.9)
Table 3 Disclosure status and types of family support of
the study participants, JUSH, southwest Ethiopia, 2009
Characteristics Frequency(Percentage)
Disclosure Status(HIV/AIDS) (N = 290) *
Wife/husband 147(50.7)
Parents 129(44.5)
Children 81(27.9)
Neighbors 127(43.8)
Friends 150(51.7)
Relatives 99(34.1)
All relatives and Neighbors 53(18.3)
Others 6(2.1)
Support From family (N = 265)
Emotional/Psychological 122(46.0)
Financial 41(15.5)
Physical care and support 63(23.8)
Food provision 39(14.7)
* More than one answer is possible.
Table 4 Self reported dose/treatment, Schedule/Program
and food Adherence among the respondents JUSH,
South west Ethiopia, 2009
Characteristics Frequency
(Percentage)
Self Reported Dose Adherence (Last 7 Days) (N =
319)
Adhered 303(95.0)
Not Adhered 16(5.0)
Self Reported Schedule Adherence (Last 7 Days)
(N = 319)
Adhered 255(79.9)
Not Adhered 64(20.1)
Self Reported Food Adherence (Last 7 Days) (N =
319)
Adhered 286(89.7)
Non Adhered 33(10.3)
Over all Adherence (N = 319)
Adhered 231(72.4)
Not Adhered 88(27.6)
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with ≥ 95% of prescribed doses in the last 7 days. Other
studies conducted in developed countries demonstrated
that the rates of adherence by self-report ranged from
40% to 70% [26-28]. Even in Botswana, fifty-four percent
of patients in the study were adherent by self-report
with 95% of prescribed doses [29]. Other studies in
developing countries have shown comparable or better
levels of individual adherence than what is seen in
North American and European populations [29,30].
According to a prospective study in Southwest Ethiopia,
384 (96%) and 361(94.3%) of the study subjects were
adherent based on self-report of missed doses (dose
adherence) in a one-week recall at base line (M0) and
follow up visit (M3) respectively. Three hundred eighty
nine (97.2%) and 373 (97.4%) of the study subjects
always followed the time restrictions (time adherence)
agreed upon with their providers at M0 and M3 respec-
tively. Three hundred thirty eight (84.5%) and 319
(83.3%) subjects followed instructions related to food
Figure 1 Reasons given for missing to take ART medication among the respondents JUSH, South west Ethiopia, 2009.
Table 5 Final logistic regression model that predict adherence to dose, time and food in JUSH, Southwest Ethiopia,
2009
Variables Adherence Crude OR
(95% CI)
P-value Adjusted OR
(95% CI)
P-value
Adhered
N (%)
Non Adhered
N (%)
WHO stage 0.01 0.13
I 4(33.3%) 8(66.7%) 0.26(0.07-0.96) 0.17(0.042-1.18)
II 56(71.8%) 22(28.2%) 1.31(0.62-2.74) 1.19(0.54- 2.56)
III 134(77.5%) 39(22.5%) 1.76(0.91-3.41) 1.35(0.67- 2.72)
IV 37(66.1%) 19(33.9%) 1.00 1.00
Average family income Tertile 0.03 0.10
Lowest 64(69.6%) 28(30.4%) 1.00 1.00
Middle 88(71.0%) 36(29.0%) 1.04(0.20-0.93) 1.07(0.58-1.98)
Highest 70(77.8%) 20(22.2%) 1.53(0.23-0.98) 1.60(0.80-3.20)
Getting family support 0.01 0.01
No 147(78.6%) 40(21.4%) 1.00 1.00
Yes 84(63.6%) 48(36.4%) 0.48(0.29-0.78) 2.12(1.25-3.59)
Sex 0.03 0.18
Male 113(78.5%) 31(21.5%) 1.76(1.06-2.93) 0.70(0.41-1.20)
Female 118(67.4%) 57(32.6%) 1.00 1.00
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reported adherence in the study area based on the com-
bined indicator of the three adherence errors was 79.3%
at baseline and 75.7% at follow up visit [21]. Similarly,
two studies in Ethiopia reported 81.2% and 82.8% adher-
ence to more than 95% of doses [23,25]. This high rate
of adherence showed adherence to ART in resource lim-
ited country can achieve a high level of adherence than
those developed country. The overall rate of self
reported adherence in this study based on the combined
indicators of the three adherence errors was 72.4%.
Similarly, consistent finding has been documented in
similar set up [21]. Some studies in resource-rich set-
tings have documented less than 50% of patients taking
all their antiretroviral medications on time and accord-
ing to dietary instructions [31,32]. Bonolo et al. review
43 articles on adherence to HAART. They found a
mean rate of non-adherence of 30.4%, range from 5% to
67% [33]. This was much lower than our report con-
firming that patients in developing countries can achieve
good adherence despite limited resources. The possible
explanation for the greater adherence in our study
might be the majority of the participants started ART
recently, the participants were given strict adherence
counseling sessions before starting ART in the hospital.
Non-adherence takes the form of skipping a dose. In a
study of southwest Ethiopia, they found principal rea-
sons reported for skipping doses were most 38 (43.7%)
simply forget, 17 (19.5%) felt sick or ill at that time, and
11 (12.6%) ran out of medication at baseline. During the
follow up visit again the majority 14 (65.6%) simply for-
got, 4 (19%) felt sick and 4 (18%) were busy [21]. In our
study the reasons given for missing drugs were running
out of medication/drug 9(27.3%), being away from home
7(21.2%) and being busy with other things 7(21.2%) and
the rest reasons included simply forgetting, having no
food to take with the medication, fear of side effect and
feeling sick or ill at that time. Forty-eight percent of
patients asserted that they missed their doses due to
finances, while 24% listed forgetting as a primary reason
for treatment non-adherence. Other barriers to treat-
ment included running out of medications (17%), travel/
migration (13%), side effects (12%), and being too busy
(12%) [29]. Forty-one percent of subjects (71/173) stated
they never missed a dose of ARV. The 102 patients
reporting missed doses at baseline did so for a variety of
reasons, the most common of which was ‘forgetting’ to
take the medication (41%; 42/102). Other reasons
included being away from home (9%), being busy with
other activities (6%), and taste perversion (5%), or con-
cern about toxicity (4%). Less commonly listed reasons
(2%) included running out of ARV medications or anxi-
ety related to the constant reminder of their HIV infec-
tion [9]. Study subjects most commonly reported that
they missed antiretroviral doses because they were busy
or forgot, away from home, or experienced a break in
their daily routine. Smaller proportions reported missing
doses because they felt depressed or overwhelmed, were
taking intentional drug holidays, or had run out of med-
ication [34]. This implicate that the reason for skipping
a dose should be given due emphasis from clinical, dis-
pensing visit as well as during ongoing adherence coun-
seling, and follow up visit. Other interventions aimed at
maintaining adherence, and thereby optimizing the ben-
efit of effective therapies should be sought in detail by
health care workers.
There is good reason to expect that sociodemographic,
psychosocial, and clinical variables should be associated
with antiretroviral adherence and thus HIV disease
activity [34]. In this study patients with average family
income of middle and highest were more likely to have
an overall adherence than the lowest average family
income in bivariate analysis. The most common patient-
related barriers were financial constraints [29,35].
Among patients having the economic ability to receive
their medication, there was an association between the
annual income and adherence [36,37]. Findings have
also been inconsistent in defining the relationship of
lower income [6,8,37,38] to adherence. A monthly mid-
dle income was significantly associated with greater
pharmacy adherence. Low or high incomes groups
showed a higher risk for pharmacy non-adherence/eco-
nomic status, in particular patients with the highest
monthly income when compared with monthly middle
income, was retained as a predictor of poor adherence
only in the best case scenario [39]. A recently published
meta-analysis [40] examined the association between
socio-economic status and adherence to antiretroviral
therapy: out of 8 studies, only 2 prospective studies
identified low income as a predictor of non-adherence.
Other factors might be contributed for the difference
between income and adherence like educational status.
Other study also demonstrated that social support has a
paramount important for adherence uptake. In our
study patients who got family support were 2 times
more likely to adhere than those who didn’tg e tt h e
family support. Another factor facilitated adherence was
support from the family encouraging and helping to
remind them to take the treatment. Social support, such
as someone to help with the tasks of starting to rebuild
a life, assistance with cooking and assistance to grow
crops, all encouraged adherence [41]. Similarly, it has
been reported in other studies [21] as social support
was a constant predictor of adherence identified at base-
line and follow up visit, living in a couple could improve
adherence because it increases the routinization of daily
behaviors and activities (Wagner & Ryan, 2004) [42] and
better social supports for using medications were all
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meta-analysis of studies across multiple medical condi-
tions determined that adherence was more strongly and
consistently associated with functional support (i.e.,
practical/emotional support) than structural support
(i.e., living arrangement/relationship status; DiMatteo,
2004) [43]. Within the domain of functional support,
the study found that the provision of practical support
had a significantly greater influence on adherence than
emotional support [44]. Lacks of social support have
been found to be associated with lower adherence
[6,26]. Social support [36] was associated with greater
adherence. Lack of support has been associated with an
increase in suboptimal adherence [45,46]. Murphy and
colleagues reported that those with greater social sup-
port for example having reassurance from family mem-
bers, those having reliable alliances were more likely to
be adherent over the past one month [47]. This high-
lights that social support assist in reminding to take the
drugs according to the prescribed schedule and time,
hence, for adherence. So it is better to advise/counsel
our patients on initiation and continuation of HAART
to be effective.
In our study disease stage/progression had been asso-
ciated with adherence. Those participants who were in
s t a g eIw e r e7 4 %l e s sl i k e l yt oa d h e r et h a nt h o s ew h o
are in the stage IV. Similar finding has been documen-
ted in other studies. In Chinese study, symptomatic dis-
ease stage had more likely to become adhere than
asymptomatic disease stage [48]. Other factors signifi-
cantly associated with viral suppression were less severe
disease (WHO stage II or III vs WHO stage IV) [49].
Inconsistence to our finding in Cameroon, CDC stage B
patients and specially CDC stage C patients had higher
risk of pharmacy non-adherence than asymptomatic
patients. When compared with asymptomatic patients,
t h em u l t i v a r i a t ea n a l y s i sc o n f i r m e dam a r k e dr i s ko f
non-adherence for CDC stage B patients and CDC stage
C patients in the worst-case scenario in Cameroon.
However, HIV CDC clinical stage at the beginning of
treatment significantly predicted loss to follow-up: com-
pared with asymptomatic patients CDC stage A, CDC
stage B patients and specially CDC stage C patients had
greater rates of loss to follow-up [39].The possible rea-
son might be those patients in stage I were not that
much manifest the diseases/symptomatic and might feel
that they are health looking as well not concerned about
their illness as compared to those in advanced stage.
The findings of this study should be interpreted with
some limitations. Because it was conducted at a single
site, the findings may not be generalizable to dissimilar
clinical settings. Recall bias and social desirability bias
are also the possible bias which may encounter in this
study. There is no gold standard for measuring
adherence and our measurement of adherence is only
based on patients’ declarations of missed doses, schedul-
ing instructions and dietary requirements. Despite the
above limitations, the study addressed an important
issue in developing country, and inclusion of several
variables that predict adherence and to fully characterize
the study population, we include other dimension of
adherence measurement for successful treatment with
ART (adhering to scheduling and to dietary instruc-
tions), reasonably large sample size (N = 319) and had a
high participation rate.
Conclusions
The adherence rate found in this study is similar to
other resource limited setting and higher than the devel-
oped country. This study highlights emphasis should be
given for income generating activities and social sup-
ports that helps to remember the patients for medica-
tion taking and management of opportunistic infections
during the course of treatment. Further study should be
carried out in longitudinal base as adherence is a
dynamic behavioral and appropriate monitoring of
patients’ treatment apart from adherence is required to
improve the treatment outcome. Identifying factors that
contribute to non-adherence in large scale and site in
follow up study should be given a due attention in the
resource limited setting.
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